Ezh2 and cd79b mutational status over time in b-cell non-hodgkin lymphomas detected by high-throughput sequencing using minimal samples

Cancer Cytopathology

Volumn 121, Issue 7, 2013, Pages 377-386

  Saieg, Mauro Ajaj ^a   Geddie, William R ^a,b   Boerner, Scott L ^a,b   Bailey, Denis ^a,b   Crump, Michael ^b   Da Cunha Santos, Gilda ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

B cell non hodgkin lymphoma; Cd79b; Dna mutational analysis; Ezh2; Fine needle biopsy; Massarray spectrometry

Indexed keywords

ADULT; ARTICLE; BURKITT LYMPHOMA; CD79B GENE; CONTROLLED STUDY; DNA EXTRACTION; EZH2 GENE; FEMALE; FOLLICULAR LYMPHOMA; GENE MUTATION; HIGH THROUGHPUT SEQUENCING; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; NONHODGKIN LYMPHOMA; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA; AGED; B CELL LYMPHOMA; B-CELL NON-HODGKIN LYMPHOMA; CD79B; CYTODIAGNOSIS; DNA MICROARRAY; EZH2; FINE-NEEDLE BIOPSY; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MASSARRAY SPECTROMETRY; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; VERY ELDERLY;

CD79 ANTIGEN; CD79B PROTEIN, HUMAN; DNA; EZH2 PROTEIN, HUMAN; PARAFFIN; POLYCOMB REPRESSIVE COMPLEX 2;

B-CELL NON-HODGKIN LYMPHOMA; CD79B; DNA MUTATIONAL ANALYSIS; EZH2; FINE-NEEDLE BIOPSY; MASSARRAY SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD79; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOMA, B-CELL; MALE; MASS SPECTROMETRY; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARAFFIN EMBEDDING; POINT MUTATION; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84878393452     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21262     Document Type: Article

References (41)

1. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109:3879-3884.
2. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298-303.
3. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189-195.
4. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43:830- 837.
5. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88- 92.
6. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181-185.
7. Yan Q, Huang Y, Watkins AJ, et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012;97:595-598.
8. Ho L, Crabtree GR. An EZ mark to miss. Cell Stem Cell. 2008;3:577-578.
9. Rea S, Eisenhaber F, O'Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000;406:593-599. (Pubitemid 30641039)
10. Velichutina I, Shaknovich R, Geng H, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010;116:5247-5255.
11. Wigle TJ, Knutson SK, Jin L, et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett. 2011;585:3011-3014.
12. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011;117:2451-2459.
13. Naylor TL, Tang H, Ratsch BA, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res. 2011;71:2643-2653.
14. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res. 2011;17:2613-2618.
15. Dawood S, Gonzalez-Angulo AM. To biopsy or not to biopsy: is that the only question? Oncologist. 2012;17:151-153.
16. Hernandez L, Wilkerson PM, Lambros MB, et al. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. J Pathol. 2012;227:42-52.
17. Eide MB, Liestl K, Lingjaerde OC, et al. Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood. 2010;116:1489-1497.
18. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020-1026.
19. Takahashi K, Kohno T, Matsumoto S, et al. Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells. Clin Cancer Res. 2007;13:111-120. (Pubitemid 46121859)
20. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12:739-745.
21. Saieg MA, Geddie WR, Boerner SL, et al. The use of FTA cards for preserving unfixed cytological material for high-throughput molecular analysis. Cancer Cytopathol. 2012;120:206-214.
22. van Eijk R, Licht J, Schrumpf M, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One. 2011;6:e17791.
23. da Cunha Santos G, Boerner SL, Geddie WR. Maximizing the yield of lymph node cytology: Lessons learned from rapid onsite evaluation of image- and endoscopic-guided biopsies of hilar and mediastinal lymph nodes. Cancer Cytopathol. 2011;119:361-366.
24. Ali AE, Morgen EK, Geddie WR, et al. Classifying B-cell non- Hodgkin lymphoma by using MIB-1 proliferative index in fineneedle aspirates. Cancer Cytopathol. 2010;118:166-172.
25. da Cunha Santos G, Ko HM, Geddie WR, et al. Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations: results of 298 fine needle aspirates of B-cell non-Hodgkin lymphoma. Cancer Cytopathol. 2010;118:250-258.
26. da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010;116:5599-5607.
27. Bodor C, O'Riain C, Wrench D, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011;25:726-729.
28. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13:e178-e185.
29. Matolcsy A. High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression. Leuk Lymphoma. 1999;34:251-259. (Pubitemid 29385168)
30. Muller-Hermelink HK, Zettl A, Pfeifer W, Ott G. Pathology of lymphoma progression. Histopathology. 2001;38:285-306. (Pubitemid 34225023)
31. Ryan RJ, Nitta M, Borger D, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One. 2011;6:e28585.
32. d'Amore F, Chan E, Iqbal J, et al. Clonal evolution in t(14;18)- positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. Clin Cancer Res. 2008;14:7180-7187.
33. Capello D, Gloghini A, Martini M, et al. Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas. Br J Haematol. 2011;152:777-780.
34. Park SW, Chung NG, Eom HS, Yoo NJ, Lee SH. Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias. Leuk Res. 2011;35:e6-e7.
35. Fumagalli D, Gavin PG, Taniyama Y, et al. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010;10:101.
36. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn. 2011;13:64-73.
37. Da Silva L, Simpson PT, Smart CE, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 2010;12:R46.
38. Lambros MB, Wilkerson PM, Natrajan R, et al. High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform. Lab Invest. 2011;91:1491-1501.
39. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009;4:e7887.
40. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347-351. (Pubitemid 46328493)
41. Wright WT, Heggarty SV, Young IS, et al. Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin Genet. 2008;74:463-468.